Maquia Capital

Maquia Capital sits in an unusual corner of the Latin American venture landscape: a Mexico City firm built around financial-engineering muscle rather than operator-led conviction. The team is best known for using SPAC structures and listed vehicles to bring Latin American technology companies to public markets, and that capital-markets DNA shapes how they approach private investments as well. For healthcare founders, that translates into a partner who thinks early about exit architecture, balance sheet design, and the regulatory plumbing of cross-border listings, rather than one who will help you tune a clinical workflow or recruit a CMO. Maquia writes Series A and Series B checks in the $1M to $5M range, focused on health IT and digital health businesses with established commercial traction inside Mexico or with credible expansion paths into the broader region. The firm is not positioned as an AI specialist, so founders pitching pure AI/ML platforms or research-stage diagnostics will likely find better fits elsewhere; what resonates here is software-enabled healthcare with predictable revenue, defensible unit economics, and a path to either consolidation or eventual public-market readiness. The right founder profile is a CEO who already has paying customers, who can talk fluently about EBITDA conversion and working-capital cycles, and who sees Maquia not as the sole lead for a Series A but as a value-additive partner alongside operationally focused regional VCs. The wrong profile is a research-stage team still searching for product-market fit; the firm’s structures and time horizons do not reward exploratory bets. The cleanest entry path is a warm introduction from a CFO or banker in Maquia’s orbit, or from a founder in their existing portfolio who can speak to how the firm behaved through a real financing crunch. When pitching, lead with the financial picture: revenue trajectory, gross margins, the structural reasons your unit economics work in the Mexican payer and provider environment, and a credible argument for why the business could reach scale that supports a public listing or strategic exit within a defined window. Bury the technology narrative below the commercial one. Caveats are worth taking seriously. Maquia’s public-markets focus has at times outpaced its operational depth in healthcare specifically, and the firm has not built a reputation as a clinical-domain expert in the way some specialist healthtech investors in Sao Paulo or Bogota have. Treat them as a strong addition to a syndicate when you need capital-markets sophistication, not as the partner who will sit in your weekly clinical operations review. Founders who calibrate expectations accordingly will get the best of what this firm has to offer without being surprised by what it is not.